Project

BEAMER

BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe
BEAMER

PROJECT

BEAMER

Programme:

INNOVATIVE MEDICINES INITIATIVE 2 JOINT UNDERTAKING GRANT AGREEMENT NO 101034369

Duration:

1 September 2021
-
31 August 2026

Patient non-adherence to prescribed treatment poses a formidable health challenge. It affects patient health outcomes significantly, contributing to 200,000 premature deaths in the EU annually, and places a heavy economic burden on the healthcare system, leading to an estimated 125B euros in avoidable hospitalisations, emergency care and adult outpatient visits each year. Despite existing research on disease-specific medication adherence, there are few broad insights regarding how to improve adherence across healthcare. To address this, BEAMER aims to acquire a comprehensive understanding of the factors that influence patient adherence, irrespective of the therapeutic area, and enable stakeholders to design effective solutions that could promote broad and consistent impact within a real-world context.

To achieve these objectives, the project will create a generalised model of the significant factors affecting non-adherent behaviour, grounded in behavioural theory. This will allow the project team to define the problem of non-adherence and provide guidance for healthcare stakeholders to develop and implement cost-effective tools and solutions that directly target patient needs, potentially contributing to enhanced patient outcomes and reduced health system costs. Although disease-agnostic,  the model is intended to be tailorable with disease-specific inputs to increase its prediction power and optimise patient support strategies. This degree of flexibility would then enable the model to be widely applicable and responsive to ongoing changes in various populations.

PROJECT

Scope and objectives

The BEAMER’s vision is to improve the quality of life of individuals, enhance healthcare accessibility and sustainability, thereby transforming the way healthcare stakeholders engage with patients to understand their condition and adherence levels throughout their healthcare journey. An outstanding experienced consortium supports the BEAMER vision with the following specific objectives organized in four phases. These objectives are fully aligned to the IMI Call topic.

PROJECT

Consortium

Led by Pfizer, co-led by Merck KGaA (Darmstadt, Germany) and coordinated by Universidad Politécnica de Madrid (UPM) the five-year project – “BEhavioral and Adherence Model for improving quality, health outcomes and cost-effectiveness of healthcaRe (BEAMER)” – brings together 27 European partners from academia, civil society and industry to jointly address adherence to treatment.

PROJECT

BEAMER

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *